Novo Nordisk receives subpoena in the US (16 February 2011)
Read in PDF format
The office of the US Attorney for the District of Massachusetts has served Novo Nordisk with a subpoena calling for the production of documents regarding potential criminal offences relating to the company's marketing and promotion practices for the following products: NovoLog® , Levemir®, and Victoza®. Novo Nordisk will cooperate with the US Attorney in this investigation.
At this time, Novo Nordisk cannot determine or predict the outcome of this matter or assess the consequences thereof. In addition, the company cannot predict how long the investigation will take or when it will be able to provide additional information.
Further information:
Media: Investors:
Rachel Curtis Graversen Klaus Bülow Davidsen
Tel: (+45) 4442 7603 Tel: (+45) 4442 3176
[email protected] [email protected]
Kasper Roseeuw Poulsen
Tel: (+45) 4442 4471
Jannick Lindegaard
Tel: (+45) 4442 4765
In North America: In North America
Ken Inchausti Hans Rommer
Tel: (+1) 609 786 8316 Tel: (+1) 609 919 7937
[email protected] [email protected]
Company Announcement no 10 / 2011